A study conducted by Ann & Robert H. Lurie Children's Hospital of Chicago found that approximately one in six children prescribed GLP-1 medications for weight loss or diabetes developed nutritional deficiencies within a year. The research involved over 2,000 patients aged 10 to 17, revealing that vitamin D deficiency was the most prevalent issue, affecting 12.4% of the participants.
Read More
Liraglutide, marketed as Victoza and Saxenda, constituted nearly 80% of prescriptions in this study. Researchers highlighted the need for proactive nutritional monitoring in these young patients, as GLP-1 drugs can decrease appetite and food intake, which is critical for bone health and development during this vital growth period.